%0 Journal Article
%T Evaluation of the effects of botulinum toxin A injections when used to improve ease of care and comfort in children with cerebral palsy whom are non-ambulant: a double blind randomized controlled trial
%A Megan Thorley
%A Samantha Donaghey
%A Priya Edwards
%A Lisa Copeland
%A Megan Kentish
%A Kim McLennan
%A Jayne Lindsley
%A Laura Gascoigne-Pees
%A Leanne Sakzewski
%A Roslyn N Boyd
%J BMC Pediatrics
%D 2012
%I BioMed Central
%R 10.1186/1471-2431-12-120
%X This study is a double blind randomized controlled trial. Forty participants will be recruited. In cycle I, participants will be randomized to either a treatment group who will receive BoNT-A injections into selected upper and/or lower limb muscles, or a control group who will undergo sham injections. Both groups will receive occupational therapy and /or physiotherapy following injections. Groups will be assessed at baseline then compared at 4 and 16 weeks following injections or sham control. Parents, treating clinicians and assessors will be masked to group allocation. In cycle II, all participants will undergo intramuscular BoNT-A injections to selected upper and/or lower limb muscles, followed by therapy.The primary outcome measure will be change in parent ratings in identified areas of concern for their child¡¯s care and comfort, using the Canadian Occupational Performance Measure (COPM). Secondary measures will include the Care and Comfort Hypertonicity Scale (ease of care), the Cerebral Palsy Quality of Life Questionnaire (CP QoL¨CChild) (quality of life), the Caregiver Priorities and Child Health Index of Life with Disabilities Questionnaire (CPCHILD£¿) (health status) and the Paediatric Pain Profile (PPP) (pain). Adverse events will be carefully monitored by a clinician masked to group allocation.This paper outlines the theoretical basis, study hypotheses and outcome measures for a trial of BoNT-A injections and therapy for children with non-ambulant CP.Australia New Zealand Clinical Trials Registry:N12609000360213Cerebral palsy (CP) is ¡°a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain¡±. [1] p.9 Classification systems have been developed to indicate the severity of functional limitations in CP. The Gross Motor Function Classification System (GMFCS), developed by Palisano and colleagues in 1997, has bec
%K Botulinum Toxin A
%K Cerebral Palsy
%K Pain
%K Comfort
%K Double blind randomized controlled trial
%U http://www.biomedcentral.com/1471-2431/12/120